News

News 18.12.2025 Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the...

Events, External events
Event date: 19.03.2026 Date: Thursday 19 March 2026, from 09:30 to 17:00 Location Congress Center Basel (Messe Basel) Messeplatz 21 4058 Basel, Switzerland Registration: More information about the programme, speakers and exhibitors, as well as the registration form, can be found at: www.single-use.ch/basel26 On March 19 - 2026, the international world of bioprocessing, (bio)pharmaceutical production and single-use technologies will...

News 17.12.2025 Zurich, Switzerland - Topadur Pharma AG, a clinical-stage biotechnology company developing innovative therapies for vascular regeneration, today announced the appointment of PD Dr. Matthias Schäfer as Chief Executive Officer. Dr. Schäfer joined Topadur in 2024 as Chief Innovation Officer and Deputy CEO and now assumes executive leadership as the company advances...

News 15.12.2025 DINAMIQS, a Siegfried company, today announced a licensing agreement with ExcellGene to access its HEKExpress® and HEK2Express® suspension cell line technologies. These will be used in GMP manufacturing of recombinant Adeno-associated virus (rAAV) and Lentivirus (rLV) vectors for both in-vivo and ex-vivo gene therapies. Eduard Ayuso, Chief Technical Officer at DINAMIQS:...

News 15.12.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the formation of a Scientific Advisory Board (SAB) for its radiopharmaceuticals,...